Open AccessEGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma
Author(s) -
HsuanYu Chen,
Chia-Hsin Liu,
YaHsuan Chang,
ShanFu Yu,
Bing-Ching Ho,
Chung-Ping Hsu,
TsungYing Yang,
KunChieh Chen,
Kuo-Hsuan Hsu,
JengSen Tseng,
JiunYi Hsia,
ChunYi Chuang,
Chun-Lung Chang,
Yucheng Liu,
Ker-Chau Li,
GeeChen Chang,
PanChyr Yang
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.7029
Subject(s) - erbb4 , adenocarcinoma , erbb , epidermal growth factor receptor , cancer research , copy number variation , mutation , erbb3 , lung , medicine , biology , oncology , gene , cancer , genetics , receptor , genome , receptor tyrosine kinase
In this study, EGFR-activating mutation status and DNA copy number abundances of members of ErbB family were measured in 261 lung adenocarcinomas. The associations between DNA copy number abundances of ErbB family, EGFR-activating mutation status, and prognosis were explored. Results showed that DNA copy number abundances of EGFR, ERBB2, ERBB3, and ERBB4 had associations with overall survival in lung adenocarcinoma with EGFR-activating mutations. In the stratification analysis, only ERBB2 showed significant discrepancy in patients carrying wild type EGFR and other members of ErbB family in patients carrying EGFR-activating mutation. This indicated that CNAs of ErbB family had effect modifications of EGFR-activating mutation status. Findings of this study demonstrate potential molecular guidance of patient management of lung adenocarcinoma with or without EGFR-activating mutations.